Saturday, 31 October 2026European Markets

SODEXO And RELX Have A High Dividend Yield And Return On Equity In The Specialty Business Services Industry.

Loading stream...

(vianews) - sodexo (sw.pa) is among this list of stock assets with the highest dividend rate and return on equity on the specialty business services industry.

financial asset price forward dividend yield return on equity
sodexo (sw.pa) €79.48 4.07% 16.98%
relx (ren.as) €42.82 1.7% 59.12%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sodexo (sw.pa)

4.07% forward dividend yield and 16.98% return on equity

sodexo s.a. provides food services and facilities management services worldwide. it offers various on-site services, which includes corporate services, energy and resources, government and agencies, and other services; healthcare and seniors; and learning solutions to schools and universities. the company also provides food services comprising retail service, food delivery, and meal and food vouchers, as well as digital food ordering services; savings and purchase solutions, data and digital tools, and advisory services and client support; and work-life balance and employee experience solutions. in addition, it offers facility management services, including technical service management, assets management, building maintenance, access control, deep cleaning, energy management, space planning, project management, front-of-house services, grounds maintenance, waste management, hvac systems, mail management, commercial cleaning, workspace management, and pest control. services. the company was formerly known as sodexho alliance and changed its name to sodexo s.a. in 2008. sodexo s.a. was founded in 1966 and is headquartered in issy-les-moulineaux, france.

earnings per share

as for profitability, sodexo has a trailing twelve months eps of €3.8.

pe ratio

sodexo has a trailing twelve months price to earnings ratio of 20.92. meaning, the purchaser of the share is investing €20.92 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.98%.

moving average

sodexo's value is under its 50-day moving average of €82.80 and under its 200-day moving average of €80.00.

yearly top and bottom value

sodexo's stock is valued at €79.48 at 12:40 est, way under its 52-week high of €89.40 and way above its 52-week low of €67.18.

volatility

sodexo's last week, last month's, and last quarter's current intraday variation average was a negative 0.08%, a negative 0.28%, and a positive 1.18%.

sodexo's highest amplitude of average volatility was 1.77% (last week), 1.22% (last month), and 1.18% (last quarter).

more news about sodexo.

2. relx (ren.as)

1.7% forward dividend yield and 59.12% return on equity

relx plc, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in north america, europe, and internationally. it operates through four segments: risk; scientific, technical & medical; legal; and exhibitions. the risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. the scientific, technical & medical segment provides information and data sets that help researchers and healthcare professionals to advance science and health outcomes. the legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as increases the productivity. the exhibitions segment is involved in the business that combines face-to-face with data and digital tools to help customers learn about markets, source products, and complete transactions. the company was formerly known as reed elsevier plc and changed its name to relx plc in july 2015. relx plc was incorporated in 1903 and is headquartered in london, the united kingdom.

earnings per share

as for profitability, relx has a trailing twelve months eps of €1.2.

pe ratio

relx has a trailing twelve months price to earnings ratio of 35.68. meaning, the purchaser of the share is investing €35.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 59.12%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on aug 1, 2024, the estimated forward annual dividend rate is 0.71 and the estimated forward annual dividend yield is 1.7%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, relx's stock is considered to be overbought (>=80).

moving average

relx's worth is higher than its 50-day moving average of €41.91 and above its 200-day moving average of €39.73.

more news about relx.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com